291 related articles for article (PubMed ID: 34683975)
1. Amorphous Solid Dispersions (ASDs): The Influence of Material Properties, Manufacturing Processes and Analytical Technologies in Drug Product Development.
Iyer R; Petrovska Jovanovska V; Berginc K; Jaklič M; Fabiani F; Harlacher C; Huzjak T; Sanchez-Felix MV
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683975
[TBL] [Abstract][Full Text] [Related]
2. Continuous Manufacturing and Molecular Modeling of Pharmaceutical Amorphous Solid Dispersions.
Nambiar AG; Singh M; Mali AR; Serrano DR; Kumar R; Healy AM; Agrawal AK; Kumar D
AAPS PharmSciTech; 2022 Sep; 23(7):249. PubMed ID: 36056225
[TBL] [Abstract][Full Text] [Related]
3. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations and marketed products.
Pandi P; Bulusu R; Kommineni N; Khan W; Singh M
Int J Pharm; 2020 Aug; 586():119560. PubMed ID: 32565285
[TBL] [Abstract][Full Text] [Related]
4. Ternary Solid Dispersions: A Review of the Preparation, Characterization, Mechanism of Drug Release, and Physical Stability.
Budiman A; Lailasari E; Nurani NV; Yunita EN; Anastasya G; Aulia RN; Lestari IN; Subra L; Aulifa DL
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631330
[TBL] [Abstract][Full Text] [Related]
5. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
Baghel S; Cathcart H; O'Reilly NJ
Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
[TBL] [Abstract][Full Text] [Related]
6. Navigating the Solution to Drug Formulation Problems at Research and Development Stages by Amorphous Solid Dispersion Technology.
Tripathi D; B H MP; Sahoo J; Kumari J
Recent Adv Drug Deliv Formul; 2023 Dec; ():. PubMed ID: 38062659
[TBL] [Abstract][Full Text] [Related]
7. Amorphous Solid Dispersions or Prodrugs: Complementary Strategies to Increase Drug Absorption.
Rumondor ACF; Dhareshwar SS; Kesisoglou F
J Pharm Sci; 2016 Sep; 105(9):2498-2508. PubMed ID: 26886316
[TBL] [Abstract][Full Text] [Related]
8. Microfluidics-on-a-chip for designing celecoxib-based amorphous solid dispersions: when the process shapes the product.
Figueiredo J; Mendes M; Pais A; Sousa J; Vitorino C
Drug Deliv Transl Res; 2024 Jun; ():. PubMed ID: 38861140
[TBL] [Abstract][Full Text] [Related]
9. Ternary solid dispersions: classification and formulation considerations.
Borde S; Paul SK; Chauhan H
Drug Dev Ind Pharm; 2021 Jul; 47(7):1011-1028. PubMed ID: 33818224
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.
Ricarte RG; Van Zee NJ; Li Z; Johnson LM; Lodge TP; Hillmyer MA
Mol Pharm; 2019 Oct; 16(10):4089-4103. PubMed ID: 31487183
[TBL] [Abstract][Full Text] [Related]
12. A systematic and robust assessment of hot-melt extrusion-based amorphous solid dispersions: Theoretical prediction to practical implementation.
Alzahrani A; Nyavanandi D; Mandati P; Youssef AAA; Narala S; Bandari S; Repka M
Int J Pharm; 2022 Aug; 624():121951. PubMed ID: 35753536
[TBL] [Abstract][Full Text] [Related]
13. Advances in the development of amorphous solid dispersions: The role of polymeric carriers.
Zhang J; Guo M; Luo M; Cai T
Asian J Pharm Sci; 2023 Jul; 18(4):100834. PubMed ID: 37635801
[TBL] [Abstract][Full Text] [Related]
14. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
15. Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review.
Yu DG; Li JJ; Williams GR; Zhao M
J Control Release; 2018 Dec; 292():91-110. PubMed ID: 30118788
[TBL] [Abstract][Full Text] [Related]
16. Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development.
He Y; Ho C
J Pharm Sci; 2015 Oct; 104(10):3237-58. PubMed ID: 26175316
[TBL] [Abstract][Full Text] [Related]
17. A Mechanistic Model for Predicting the Physical Stability of Amorphous Solid Dispersions.
Ojo AT; Lee PI
J Pharm Sci; 2021 Apr; 110(4):1495-1512. PubMed ID: 32818440
[TBL] [Abstract][Full Text] [Related]
18. Spray Encapsulation as a Formulation Strategy for Drug-Based Room Temperature Ionic Liquids: Exploiting Drug-Polymer Immiscibility to Enable Processing for Solid Dosage Forms.
Stocker MW; Healy AM; Ferguson S
Mol Pharm; 2020 Sep; 17(9):3412-3424. PubMed ID: 32852215
[TBL] [Abstract][Full Text] [Related]
19.
Jermain SV; Lowinger MB; Ellenberger DJ; Miller DA; Su Y; Williams RO
Mol Pharm; 2020 Aug; 17(8):2789-2808. PubMed ID: 32520562
[TBL] [Abstract][Full Text] [Related]
20. Hydrogenated phospholipid, a promising excipient in amorphous solid dispersions of fenofibrate for oral delivery: Preparation and in-vitro biopharmaceutical characterization.
Czajkowski M; Jacobsen AC; Bauer-Brandl A; Brandl M; Skupin-Mrugalska P
Int J Pharm; 2023 Sep; 644():123294. PubMed ID: 37544387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
